The aim of this review is to discuss the emerging role of DDR alterations in the pathophysiology of two chronic myeloproliferative disease states, BCR-ABL-positive CML and JAK2 V617F-positive PV. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.